このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ASTAR: Sacituzumab Govitecan For Breast Cancer (ASTAR)

2026年11月13日 更新者:Laura M. Spring, MD、Massachusetts General Hospital

A Phase II Study of Adjuvant Sacituzumab Govitecan (SG) in High-risk Early-stage HR+/HER2- Breast Cancer (ASTAR)

The goal of this clinical trial is to assess the safety and tolerability of sacituzumab govitecan followed by docetaxel and cyclophosphamide for individuals with high-risk early-stage HR+/HER2- breast cancer. The main questions it aims to answer are:

  • Is sacituzumab govitecan safe for individuals with this type of cancer?
  • Is sacituzumab govitecan effective in curing this type of cancer? Participants will receive up to 8 cycles of sacituzumab govitecan with chemotherapy.

調査の概要

詳細な説明

This is a single-arm, open-label, phase II study evaluating the toxicity and feasibility of sacituzumab govitecan (SG) followed by docetaxel/cyclophosphamide (TC) in patients with high-risk early-stage HR+/HER2- breast cancer. Participants will receive four 21-day cycles of the study treatment, sacituzumab govitecan, and then four 21-day cycles of docetaxel and cyclophosphamide chemotherapy, for a total of eight cycles or 24 weeks. Participants will be followed for up to three years after completing study treatment. It is expected that about 32 people will take part in this research study. Gilead Sciences, Inc., a biopharmaceutical company, is supporting this research study by providing the study drug, sacituzumab govitecan, and funding for research activities. The U.S. Food and Drug Administration (FDA) has not approved sacituzumab govitecan for this specific disease, but it has been approved for use in other stages of breast cancer. Sacituzumab govitecan is a lab-made, humanized monoclonal antibody drug-conjugate. "Humanized" means it is primarily made to look like a natural human antibody, so the body tolerates it better. An antibody is a protein made by your immune system that recognizes and sticks to harmful things like bacteria, viruses, or cancer cells so your body can fight them off. Sacituzumab govitecan is a type of targeted cancer treatment made by linking an antibody that fights cancer cells and a chemotherapy drug that can kill the cancer cells together. Use of an antibody allows the chemotherapy to be delivered directly to cancer cells, helping kill them while reducing damage to the rest of the body. The U.S. FDA has approved docetaxel and cyclophosphamide chemotherapy as a treatment option for this disease. Docetaxel is a type of chemotherapy that works by disrupting the function of microtubules (a hollow "tube" that helps cells keep their shape and pull apart) which helps to stop cell division. Cyclophosphamide is an alkylating agent, a type of chemotherapy medication that works by adding alkyl groups to DNA. Alkyl groups are small chemical pieces that attach to other molecules and change how those molecules work. This interferes with the cells' ability to make copies of itself, causing cell death in rapidly dividing cells, such as cancer cells. Together, docetaxel essentially "freezes" cells so they can't finish dividing and cyclophosphamide damages their DNA so they cannot make new copies, eventually leading to cell death. Using these drugs together helps attack leftover cancer cells in different ways at the same time, helping the treatment to be more effective and killing cancer cells. The U.S. FDA has not approved sacituzumab govitecan followed by docetaxel and cyclophosphamide chemotherapy as a treatment option for this disease.

研究の種類

介入

入学 (推定)

32

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Massachusetts
      • Boston、Massachusetts、アメリカ、02114
        • Massachusetts General Hospital
        • コンタクト:
      • Boston、Massachusetts、アメリカ、02115
        • Brigham & Women's Hospital
        • コンタクト:
      • Danvers、Massachusetts、アメリカ、01923
        • Mass General Cancer Center in Danvers
        • コンタクト:
      • Newton、Massachusetts、アメリカ、02462
        • Mass General Cancer Center at Newton-Wellesley Hospital
        • コンタクト:
      • Waltham、Massachusetts、アメリカ、02451
        • Mass General Waltham
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Female or male patients ≥ 18 years of age.
  • Histologically confirmed diagnosis of invasive breast cancer after completion of definitive surgical management (either mastectomy or lumpectomy) within 3-12 weeks of starting study treatment.
  • Participants must have biopsy proven hormone receptor positive (HR+) (either/both estrogen receptor (ER) and progesterone receptor (PR) positive) HER2 negative (HER2-), invasive breast cancer. ER, PR, and HER2 positivity will be determined per ASCO/CAP guidelines by institutional (local) assessment, with expression of either the estrogen receptor (ER) or progesterone receptor (PR) at least 10%. Patients with multi-focal and multi-centric disease are eligible provided all histologically examined lesions are HR+/HER2- (local assessment). The need to biopsy additional lesions is per the discretion of the treating physician. Patients with bilateral invasive breast cancer are eligible provided all histologically examined lesions are HR+/HER2- (local assessment).
  • Anatomic stage IIB-III breast cancer according to AJCC 8th edition TNM staging, based on final surgical pathology. Patients with only lymph node micrometastases (pN1mi) are not eligible. Participants must have no evidence of distant metastatic disease (M0). Staging scans are not required and may be obtained at the discretion of the treating physician.
  • Both pre- and postmenopausal women are eligible.
  • ECOG performance status = 0, 1, 2 (Karnofsky ≥60%, see Appendix A)
  • Ability to understand and the willingness to sign a written informed consent form (ICF). Patient has signed the ICF prior to any screening procedures being performed and is able to comply with protocol requirements.
  • Patient has adequate bone marrow and organ function as defined by the following laboratory values at screening:
  • Absolute neutrophil count (ANC) ≥ 1,500 per mm3
  • Platelets ≥ 100,000 per mm3
  • Hemoglobin ≥9.0 g/dL
  • INR ≤1.5
  • Serum creatinine <1.5 mg/dL or creatinine clearance ≥50 mL/min
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 x ULN
  • Total bilirubin ≤1.5 x ULN or in patients with well-documented Gilbert's Syndrome direct bilirubin ≤1.5 x ULN

Exclusion Criteria:

  • Inflammatory breast cancer or locally recurrent breast cancer
  • Participants currently receiving systemic therapy, including endocrine therapy, for any other malignancy or having received systemic therapy for a malignancy in the past 3 years
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including any of the following:
  • History of angina pectoris, symptomatic pericarditis, coronary artery bypass graft (CABG) or myocardial infarction within 6 months prior to study entry
  • History of cardiac failure, known cardiomyopathy (LVEF < 50%; new LVEF assessment is not specifically required for this trial), significant/symptomatic bradycardia, Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following:
  • Known risk to prolong the QT interval or induce Torsade's de Pointes.
  • Uncorrected hypomagnesemia or hypokalemia.
  • Systolic Blood Pressure (SBP) >160 mmHg or <90 mmHg.
  • Bradycardia (heart rate <50 at rest), by ECG or pulse. On screening, inability to determine the QTcF interval on the ECG (i.e.: unreadable or not interpretable) or QTcF >470 screening ECG
  • Pregnant or breast-feeding women are excluded from this study because the safety of study regimen in this population is not established
  • Participants with well-controlled HIV infection are eligible if they are on stable antiretroviral therapy and have no evidence of uncontrolled infection. Participants with chronic hepatitis B infection are eligible if viral replication is adequately suppressed with antiviral therapy when indicated. Participants with hepatitis C infection are eligible if they have been successfully treated or have stable disease with no evidence of clinically significant hepatic dysfunction. Separate HIV, hepatitis B, or hepatitis C testing for this trial is not required unless clinically indicated.
  • Participants who are currently receiving chronic treatment with corticosteroids at a dose ≥ 10 mg of prednisone (or its glucocorticoid equivalent) per day (inhaled and topical steroids are allowed), or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug
  • Participants who are not good candidates for the study (as per investigator judgement)
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 6 months after the last dose of sacituzumab govitecan, 2 months after the last dose of docetaxel, and for 1 year after the last dose of cyclophosphamide. Male participants capable of impregnating a woman must use highly effective methods of contraception throughout the study and for 3 months after the last dose of sacituzumab govitecan and for 4 months after the last doses of docetaxel and cyclophosphamide. Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential. Barrier method plus spermicide alone is not considered highly effective contraception but could be combined with other highly effective contraception methods. Highly effective contraception methods include:
  • Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
  • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
  • Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
  • Prior treatment involving topoisomerase-I targeting agents, including ADCs

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Sacituzumab Govitecan with Chemotherapy

Participants will be given sacituzumab govitecan (SG) at a pre-determined dose on days 1 and 8 of each 21-day cycle into their vein (by intravenous infusion). This will continue for up to 4 cycles. After completing 4 cycles of SG, participants will be given docetaxel and cyclophosphamide chemotherapy at the pre-determined doses on day 1 of each 21-day cycle into their vein. This will continue for up to 4 cycles, for a total of 8 treatment cycles from the start of treatment with SG.

Intravenous infusion administered on days 1 and 8 of cycles 1-4 (one cycle is 21 days).

Intravenous infusion administered on day 1 of cycles 5-8 (one cycle is 21 days).

Intravenous infusion administered on day 1 of cycles 5-8 (one cycle is 21 days).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of Grade 3 or Higher Treatment-Emergent Adverse Events (TEAEs)
時間枠:Screening to 2 years after completion of protocol therapy or until death, whichever occurs first.

TEAEs are defined/graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE); version in effect at study initiation. The proportion of patients experiencing at least 1 grade 3 or higher TEAE will be summarized both as a point estimate and by its respective 95% confidence interval. Statistical significance is declared at the one-sided 5% type I error by a two-stage binomial test. In addition to the estimation of the one-side 95% confidence interval around the grade 3 or higher TEAE rate, equivalent two-sided 90% confidence intervals will be estimated for better clinical interpretability.

Screening to 2 years after completion of protocol therapy or until death, whichever occurs first.

二次結果の測定

結果測定
メジャーの説明
時間枠
Proportion of Patients who Complete the Planned Study Regimen (Tolerability)
時間枠:Day first participant is enrolled to 2 years after the last participant completes protocol therapy.

Tolerability is defined as the proportion of patients who complete the planned study regimen without premature discontinuation due to toxicity. The completion rate and exact two-sided 95% confidence intervals will be reported. If all 32 patients are enrolled, the maximum half-width of the 95% confidence interval is approximately +/-0.18. Reasons for dose-reduction, delay, or discontinuation will be summarized.

Day first participant is enrolled to 2 years after the last participant completes protocol therapy.
2-Year Recurrence-Free Survival (RFS)
時間枠:Day 1 of cycle 1 (each cycle is 21 days) to 2 years after day 1 of cycle 1, day of documented disease recurrence, or death, whichever occurs first.

RFS is defined as the time from treatment initiation to documented invasive breast cancer recurrence (local, regional, or distant) or death from any cause, whichever occurs first. Participants alive without disease recurrence will be censored at the date of last disease evaluation. The 2-year RFS rate will be estimated using the Kaplan-Meier method. Given the short follow-up window and long duration of response of these patients, median RFS may not be achieved, at which point the probability for being recurrence free for 2 years will be estimated along with its respective 95% confidence interval (CI). Assuming 90% of the subjects are recurrence free at 2 years, the 95% CI is expected to extend approximately 17 percentage points below and 7 percentage points about the point estimate (approximately 73%-97%). Assuming an 80% 2-year RFS, the 95% CI is expected to extend approximately 18 percentage points below and 10 percentage points about the point estimate (approximately 62%-90%).

Day 1 of cycle 1 (each cycle is 21 days) to 2 years after day 1 of cycle 1, day of documented disease recurrence, or death, whichever occurs first.
Changes in Circulating tumor DNA (ctDNA) During and After Administration of Study Therapy
時間枠:Screening to 2 years after completion of protocol therapy or until death, whichever occurs first.

ctDNA will be analyzed longitudinally during treatment and follow-up using a general linear mixed model with a random intercept per subject and at minimum a fixed effect for time. ctDNA positively rates at predefined time points will be estimated and summarized. Changes in ctDNA allele fraction or tumor fraction over time will be summarized by slope and intercept estimates from the mixed model. 95% confidence interval will also be reported from the model.

Screening to 2 years after completion of protocol therapy or until death, whichever occurs first.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

捜査官

  • 主任研究者:Laura Spring, MD、Massachusetts General Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年4月21日

一次修了 (推定)

2028年9月1日

研究の完了 (推定)

2030年9月1日

試験登録日

最初に提出

2026年11月13日

QC基準を満たした最初の提出物

2026年11月13日

最初の投稿 (実際)

2026年11月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月13日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Request may be directed to: Dr. Laura Spring at 617-726-6500 or LSpring@mgh.harvard.edu. The protocol and statistical analysis plan will be made available on ClinicalTrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD 共有時間枠

Data can be shared no earlier than 1 year following the date of publication.

IPD 共有アクセス基準

Contact the Partners Innovations team at http://www.partners.org/innovation

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する